{"disease":{"id":"malignant-mesothelioma","name":"malignant mesothelioma"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"ipilimumab","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"pemetrexed-disodium","indication_name":"Malignant Pleural Mesothelioma - Initial Treatment with Cisplatin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PEMETREXED DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"pemetrexed","indication_name":"Malignant mesothelioma of pleura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alimta","generic_name":"pemetrexed","company_name":"Actavis","drug_phase":"marketed","molecular_target":"Folate receptor alpha","drug_class":"Folate Analog Metabolic Inhibitor","quality_score":75,"revenue":null,"mechanism":"Alimta works by inhibiting the enzyme dihydrofolate reductase, which is necessary for DNA synthesis and cell division."},{"drug_id":"yervoy","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"pemetrexed-dipotassium","indication_name":"Initial treatment of malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PEMETREXED DIPOTASSIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Folate Analog Metabolic Inhibitor [EPC]","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"pemetrexe","indication_name":"Malignant mesothelioma of pleura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pemetrexe","company_name":"Rongjie Tao","drug_phase":"marketed","molecular_target":"Serine hydroxymethyltransferase, cytosolic, Folate receptor beta, Folate transporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Unresectable Malignant Pleural Mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":8,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT00242723","title":"Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining","phase":"","overall_status":"RECRUITING","enrollment_count":1310,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01843374","title":"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":571,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT02214134","title":"SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access","phase":"","overall_status":"COMPLETED","enrollment_count":539,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT05042557","title":"Real World Study of MPM in China","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT02349412","title":"Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":405,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05193006","title":"Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04334759","title":"DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":214,"lead_sponsor_name":"PrECOG, LLC.","has_results":false},{"nct_id":"NCT05308966","title":"Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)","phase":"","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Groupe Francais De Pneumo-Cancerologie","has_results":false},{"nct_id":"NCT04843007","title":"Alvopem® (Pemetrexed) Safety Assessment","phase":"","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"NanoAlvand","has_results":true},{"nct_id":"NCT05278975","title":"Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":186,"lead_sponsor_name":"RS Oncology LLC","has_results":false},{"nct_id":"NCT01655225","title":"A Study of LY3023414 in Participants With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT00334594","title":"Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT05655078","title":"Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma","phase":"NA","overall_status":"RECRUITING","enrollment_count":148,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03074513","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":133,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01064648","title":"Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":117,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04775446","title":"Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Centre Hospitalier Intercommunal Creteil","has_results":false},{"nct_id":"NCT06946498","title":"First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"National and Kapodistrian University of Athens","has_results":false},{"nct_id":"NCT06566079","title":"Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"InSilico Medicine Hong Kong Limited","has_results":false},{"nct_id":"NCT02761863","title":"Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT00738582","title":"An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Morphotek","has_results":true},{"nct_id":"NCT04491942","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05461430","title":"Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Travera Inc","has_results":false},{"nct_id":"NCT04480372","title":"SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT05228015","title":"Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT05001880","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02399371","title":"Pembrolizumab in Treating Patients With Malignant Mesothelioma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":65,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT02141347","title":"Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06057935","title":"A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT01675765","title":"Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Aduro Biotech, Inc.","has_results":true},{"nct_id":"NCT03907852","title":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"TCR2 Therapeutics","has_results":false},{"nct_id":"NCT00652574","title":"Dasatinib in Resectable Malignant Pleural Mesothelioma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03007030","title":"Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07131345","title":"Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":55,"lead_sponsor_name":"National Cancer Center, China","has_results":false},{"nct_id":"NCT03126630","title":"Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":49,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01291420","title":"Dendritic Cell Vaccination for Patients with Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false},{"nct_id":"NCT03213301","title":"Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT01265433","title":"Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Sellas Life Sciences Group","has_results":true},{"nct_id":"NCT05077111","title":"A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Mohamed Reda Ashour","has_results":false},{"nct_id":"NCT05660616","title":"Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT03177668","title":"Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Kissei Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04462809","title":"Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT02863055","title":"Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":37,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT03507452","title":"First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07510815","title":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT02004028","title":"Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":35,"lead_sponsor_name":"Verastem, Inc.","has_results":true},{"nct_id":"NCT02611037","title":"Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT01211275","title":"Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT04823741","title":"Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}